Cargando…
Correction: Systematic review and meta-analysis comparing zoledronic acid administered at 12-week and 4-week intervals in patients with bone metastasis
Autores principales: | Cao, Ling, Yang, Yong-Jing, Diao, Jian-Dong, Zhang, Xu-He, Liu, Yan-Ling, Wang, Bo-Yu, Li, Zhi-Wen, Liu, Shi-Xin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6114954/ https://www.ncbi.nlm.nih.gov/pubmed/30181818 http://dx.doi.org/10.18632/oncotarget.26009 |
Ejemplares similares
-
Systematic review and meta-analysis comparing zoledronic acid administered at 12-week and 4-week intervals in patients with bone metastasis
por: Cao, Ling, et al.
Publicado: (2017) -
Correction: Humanized bone facilitates prostate cancer metastasis and recapitulates therapeutic effects of Zoledronic acid in vivo
por: Landgraf, Marietta, et al.
Publicado: (2020) -
Correction to: Standard (8 weeks) vs long (12 weeks) timing to minimally-invasive surgery after NeoAdjuvant Chemoradiotherapy for rectal cancer: a multicenter randomized controlled parallel group trial (TiMiSNAR)
por: Monsellato, Igor, et al.
Publicado: (2020) -
Correction: Liao et al. Twelve-Week Lower Trapezius-Centred Muscular Training Regimen in University Archers. Healthcare 2022, 10, 171
por: Liao, Chien-Nan, et al.
Publicado: (2022) -
Correction to: Fremanezumab in the prevention of high-frequency episodic and chronic migraine: a 12-week, multicenter, real-life, cohort study (the FRIEND study)
por: Barbanti, Piero, et al.
Publicado: (2022)